15 Best Micro and Small Cap Stocks to Buy According to Jim Simons’ Renaissance Technologies

12. Sarepta Therapeutics Inc (NASDAQ:SRPT)

Renaissance Technologies Equity Stake: $36.23 Million

Number of Hedge Fund Holders: 36

Stock Upside Potential: 28.22%

Market Cap: $1.79 Billion

Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. 36 elite hedge funds have positions in Sarepta Therapeutics Inc (NASDAQ:SRPT) stock, and analysts on the Street expect this gene therapy stock to pop at least 28% from its current level.

On May 6, the management of Sarepta Therapeutics hosted a call to discuss Q1 2026 results and to provide operational updates. Many things stood out from that call, including the company’s solid financial position.

Sarepta exited Q1 with $748.3 million in cash and investments, and with this, the management said the company is positioned for self-funded growth. As the CEO Douglas Ingram explained, this financial strength means a lot to the company, including the ability to fully fund the advancement of pipeline projects without relying on the equity markets.

For 2026, Sarepta has outlined a set of priorities. These include stabilizing the business, restoring confidence and growth, maintaining financial strength, and advancing the pipeline. The company says its flagship product Elevidys is positioned to return to growth after safety concerns slowed it down. Increased physician engagement and a growing body of compelling evidence supporting Elevidys are some of the factors expected to fuel the therapy’s growth.

The management expects the company to remain profitable and keep growing its cash balance. For 2026, revenue is projected to be in the range of $1.2 billion to $1.4 billion.

Sarepta Therapeutics Inc (NASDAQ:SRPT) is a biotech company that develops gene therapies for neuromuscular and central nervous system conditions. The company targets rare diseases with unmet treatment needs. Sarepta has several commercial products and an expansive pipeline of potential products.